Profile data is unavailable for this security.
About the company
Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.
- Revenue in NZD (TTM)16.83m
- Net income in NZD-34.55m
- Incorporated2001
- Employees0.00
- LocationPacific Edge LtdCentre for Innovation, 87 St David St,PO Box 56DUNEDIN 9016New ZealandNZL
- Phone+64 35776733
- Fax+64 39749393
- Websitehttps://www.pacificedgedx.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharma Foods International Co., Ltd. | 714.51m | -20.27m | 188.44m | 613.00 | -- | 1.85 | -- | 0.2637 | -64.99 | -64.99 | 2,293.41 | 324.90 | 2.02 | 1.70 | 15.01 | 108,280,600.00 | -5.74 | 6.92 | -16.01 | 18.90 | 80.32 | 80.70 | -2.84 | 3.34 | 0.6512 | -8.21 | 0.6151 | 33.24 | 5.01 | 33.56 | -88.52 | -11.84 | -0.161 | 24.08 |
| Pacific Edge Ltd | 16.83m | -34.55m | 204.52m | 0.00 | -- | 7.60 | -- | 12.15 | -0.0409 | -0.0409 | 0.02 | 0.0263 | 0.3935 | -- | 3.78 | -- | -80.80 | -36.39 | -98.90 | -40.47 | -- | -- | -205.33 | -142.52 | 3.83 | -- | 0.0795 | -- | -8.62 | 37.97 | -1.36 | -- | 47.39 | -- |
| Sunho Biologics Inc | 0.00 | -20.29m | 209.27m | 128.00 | -- | 1.76 | -- | -- | -0.6181 | -0.6181 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -14.33 | -- | -15.84 | -- | -- | -- | -- | -- | 6.57 | -- | 0.1242 | -- | -- | -- | 39.74 | -- | -- | -- |
| Brii Biosciences Ltd | 0.00 | -92.88m | 227.61m | 96.00 | -- | 0.3693 | -- | -- | -0.5865 | -0.5865 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -14.05 | -49.92 | -14.09 | -54.57 | -- | -- | -- | -12,750.27 | -- | -- | 0.003 | -- | -100.00 | -- | -190.66 | -- | -33.13 | -- |
| B&K Corp Ltd | 64.53k | -45.15m | 228.06m | 100.00 | -- | 10.91 | -- | 3,534.44 | -1.76 | -1.76 | 0.0025 | 0.8165 | -- | -- | -- | -- | -- | -- | -- | -- | 92.34 | -- | -69,968.59 | -- | -- | -- | 0.0371 | -- | -44.70 | -- | -101.78 | -- | -- | -- |
| Energenesis Biomedical Co Ltd | 399.17k | -13.04m | 228.25m | -- | -- | 4.28 | -- | 571.80 | -2.87 | -2.87 | 0.088 | 11.21 | 0.0087 | 2.39 | 7.47 | -- | -28.56 | -26.17 | -29.51 | -27.03 | 77.30 | 71.32 | -3,266.22 | -2,733.90 | 34.44 | -- | 0.0162 | -- | 8.26 | 4.39 | 11.25 | -- | -17.18 | -- |
| Holder | Shares | % Held |
|---|---|---|
| ANZ New Zealand Investments Ltd.as of 13 Aug 2025 | 169.56m | 16.58% |
| Harbour Asset Management Ltd.as of 28 Jan 2026 | 113.67m | 11.12% |
| BT Funds Management (NZ) Ltd.as of 14 Aug 2025 | 53.68m | 5.25% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 15.13m | 1.48% |
| Kernel Wealth Ltd.as of 31 Jan 2026 | 3.06m | 0.30% |
| FCA Corp.as of 31 Dec 2025 | 800.00k | 0.08% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 534.85k | 0.05% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 133.63k | 0.01% |
| DFA Australia Ltd.as of 31 Jan 2026 | 68.18k | 0.01% |
